Congreso de Investigacion Hematologia y Oncologia (ACHO)

Attendees, exhibitors & solutions

Who this event is for

Industry trends

Key trends shaping this market and its wider industry.

Arrival airports

Choose from the following airports, with convenient access to the event and venue.

Hotel tiers

A range of accommodation options near the venue and across key areas.

Local transport

Get around the city with these convenient transport options.

Frequently asked

Glossary

1

Hematology

Medical specialty focused on blood, bone marrow and lymphatic disorders, including anemias, coagulopathies and hematologic malignancies.

2

Oncology

Specialty focused on the diagnosis, treatment and prevention of cancer, including solid tumours and blood cancers.

3

Hemato-oncology

Overlap field covering blood cancers such as leukemia, lymphoma and myeloma, often managed jointly by hematologists and oncologists.

4

Leukemia

Cancer of blood-forming tissues, including acute and chronic myeloid or lymphoid forms; treatment may include chemotherapy, targeted therapy and transplant.

5

Lymphoma

Cancer of lymphocytes, broadly grouped into Hodgkin and non-Hodgkin lymphoma; staging and subtype drive therapy.

6

Multiple myeloma

Plasma-cell malignancy with bone, kidney and immune effects; treatment often combines proteasome inhibitors, immunomodulatory drugs and antibodies.

7

Myelodysplastic syndromes (MDS)

Clonal bone-marrow disorders with ineffective blood production and variable risk of progression to acute myeloid leukemia.

8

Chemotherapy

Cytotoxic drug treatment that kills rapidly dividing cells; used in curative and palliative settings and often combined with other modalities.

9

Immunotherapy

Treatment that engages the immune system, including checkpoint inhibitors and bispecific antibodies; a fast-moving area in oncology.

10

CAR-T cell therapy

Engineered T-cell therapy for selected blood cancers; requires specialized collection, manufacturing, infusion and toxicity monitoring.

11

Hematopoietic stem cell transplant (HSCT)

Procedure using autologous or allogeneic stem cells to restore marrow function after high-dose therapy or treat selected hematologic diseases.

12

Cytogenetics

Study of chromosomes in tumour or marrow cells; abnormalities help classify risk and guide treatment in leukemia, MDS and myeloma.

13

Molecular profiling

Testing for gene mutations, fusions and expression patterns, for example with NGS, to match patients to targeted therapies and trials.

14

Minimal residual disease (MRD)

Detection of small numbers of cancer cells after treatment; increasingly used to assess response and guide decisions in leukemia and myeloma.

15

Tumor board

Multidisciplinary meeting where surgeons, oncologists, radiologists, pathologists and others agree on diagnosis and treatment plans.

16

Neutropenia

Abnormally low neutrophil count, often chemotherapy-related; raises infection risk and may require growth factors or dose adjustment.

17

Thrombocytopenia

Low platelet count that can increase bleeding risk; causes include marrow disease, chemotherapy and immune destruction.

18

Supportive care

Management of symptoms and treatment side effects, including antiemetics, pain control, nutrition, infection prevention and psychosocial support.

19

Palliative care

Care focused on symptom relief and quality of life for patients with serious illness, delivered alongside curative or disease-directed treatment.

20

Biomarker

Measurable biological indicator, such as a mutation or protein, used for diagnosis, prognosis or selecting targeted therapy.

21

Clinical trial

Protocol-driven research study that evaluates safety and efficacy of new treatments; often organized by phase (I-IV).

22

Relapsed or refractory disease

Disease that has returned after response or does not respond to current therapy; a common eligibility category for trials and advanced therapies.